Product image of Neosynephrine (Phenylephrine Hydrochloride) supplied by GNH India

Neosynephrine

Active Ingredient:
Phenylephrine Hydrochloride
Origin:
EU

Neosynephrine (Phenylephrine Hydrochloride)

Phenylephrine Hydrochloride, the active ingredient in Neosynephrine, is an alpha-1 adrenergic agonist presented as an ophthalmic solution for ocular use. It produces rapid pupil dilation to facilitate eye examinations and diagnostic procedures for patients undergoing routine clinical settings.

GNH India supplies Neosynephrine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratoires Europhta

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Neosynephrine, an ocular alpha‑1 adrenergic agonist, is employed to induce mydriasis for various ophthalmic assessments.
  • Eye examination: provides pupil dilation to improve visualization of intraocular structures.
  • Ocular diagnostic testing: enables clear view for imaging and laser procedures.
  • Pre‑operative ocular assessment: facilitates thorough evaluation before surgery.

How It Works

  • Phenylephrine Hydrochloride acts as a selective alpha‑1 adrenergic receptor agonist on the radial iris dilator muscle. Activation of these receptors triggers contraction of the dilator fibers, leading to relaxation of the sphincter pupillae and resulting in pupil enlargement (mydriasis). The effect is rapid, dose‑dependent, and localized to the eye when administered as an ophthalmic solution. The drug’s limited systemic absorption minimizes cardiovascular impact when used at recommended ocular concentrations.

Side Effects

Phenylephrine Hydrochloride may cause ocular and systemic adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Transient ocular redness: mild irritation at the application site.
  • Temporary blurred vision: short‑term focus disturbance after dilation.
  • Mild eye discomfort: sensation of pressure or stinging.
  • Headache: occasional mild headache following administration.

Serious or Rare Side Effects

  • Acute angle‑closure glaucoma: sudden increase in intraocular pressure requiring emergency care.
  • Systemic hypertension: significant rise in blood pressure, especially in susceptible patients.
  • Allergic reaction: rash, swelling, or severe eye inflammation.

Precautions & Warnings

When using Neosynephrine, consider the following precautions to ensure safe and effective application.

  • Assess intraocular pressure: avoid use in patients with narrow-angle glaucoma.
  • Review cardiovascular status: caution in individuals with uncontrolled hypertension.
  • Avoid concurrent mydriatics: limit combined use with other pupil‑dilating agents.
  • Monitor for systemic absorption: observe for signs of elevated blood pressure or tachycardia.
  • Store at ambient temperature: keep in the original container, protect from light and moisture.

Avoid Interactions

Phenylephrine Hydrochloride can interact with other medications; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

  • Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis when combined with phenylephrine.
  • Non‑selective beta‑blockers: may blunt ocular vasoconstrictive response and affect systemic blood pressure.

Moderate Interactions (Monitor Closely)

  • Systemic sympathomimetics (e.g., epinephrine): additive cardiovascular stimulation.
  • Antihypertensive agents (e.g., ACE inhibitors): may reduce the drug’s systemic effects, requiring blood pressure monitoring.
  • Topical ocular decongestants: concurrent use may increase local vasoconstriction and discomfort.

Frequently Asked Questions

Neosynephrine is used to induce mydriasis, or pupil dilation, during eye examinations and diagnostic procedures. By widening the pupil, clinicians can obtain a clearer view of intraocular structures, which aids in accurate assessment and treatment planning.

Phenylephrine Hydrochloride selectively stimulates alpha‑1 adrenergic receptors on the radial iris dilator muscle. This activation contracts the dilator muscle, causing the pupil to enlarge while the sphincter muscle relaxes, resulting in rapid and controlled mydriasis.

The specific dose of Neosynephrine is determined by the prescribing eye care professional based on the patient’s age, clinical condition, and the required degree of dilation. The prescriber will provide exact instructions for each individual case.

Safety data for Phenylephrine Hydrochloride in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing Neosynephrine to pregnant or breastfeeding individuals.

To order Neosynephrine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Neosynephrine (phenylephrine) produces rapid dilation by directly stimulating alpha‑1 receptors, whereas agents like tropicamide act on muscarinic receptors to cause relaxation of the sphincter muscle. Phenylephrine often provides a quicker onset but may have a higher risk of systemic cardiovascular effects compared with anticholinergic mydriatics.

Neosynephrine should be stored at ambient temperature, away from direct sunlight and moisture. Keep the product in its original container, ensure the cap is tightly closed, and avoid exposure to extreme temperatures to maintain stability and efficacy.

Neosynephrine is administered as an ophthalmic solution. The prescribed number of drops is instilled into the conjunctival sac of the affected eye(s) using a sterile technique, typically shortly before the eye examination or procedure.

The most serious risks include acute angle‑closure glaucoma, which can cause a rapid rise in intraocular pressure, and systemic hypertension, especially in patients with pre‑existing cardiovascular conditions. Prompt medical attention is required if these events occur.

Neosynephrine should be avoided in patients with known narrow‑angle or acute angle‑closure glaucoma, uncontrolled hypertension, or hypersensitivity to phenylephrine or any excipients in the formulation. Contraindications should be confirmed by the prescribing clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.